Besides guidance on screening and prevention, OPM specified that carriers must cover at least one GLP-1 weight-loss drug
Specific dose ranges should be set with your clinician not by copying a male protocol
Additionally, because many people with diabetes or who are overweight may control their condition with diet, other medications and therapies, or choose to not seek treatment, not all people who meet these clinical criteria would use GLP-1 drugs
The Lancet Regional HealthEurope
Those self-reported events involved semaglutide, tirzepatide, dulaglutide, and liraglutide, the generic names for leading GLP-1s, according to KFF
Talk to your providerthey may suggest adjustments to your treatment plan